About Prenetics Global Limited
https://www.prenetics.comPrenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test.
CEO
Sheng Wu Yeung
Compensation Summary
(Year )
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
LMR PARTNERS LLP
Shares:1.3M
Value:$29.86K
ASPEX MANAGEMENT (HK) LTD
Shares:1.17M
Value:$26.72K
CALAMOS ADVISORS LLC
Shares:200K
Value:$4.58K
Summary
Showing Top 3 of 20
About Prenetics Global Limited
https://www.prenetics.comPrenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $23.55M ▲ | $20.19M ▲ | $-7.41M ▲ | -31.45% ▲ | $-0.53 ▲ | $-6.72M ▲ |
| Q2-2025 | $17.68M ▲ | $17.35M ▼ | $-12.41M ▼ | -70.19% ▼ | $-0.94 ▼ | $-10.89M ▲ |
| Q1-2025 | $17.31M ▲ | $17.97M ▼ | $-10.39M ▲ | -60.02% ▲ | $-0.8 ▲ | $-11M ▲ |
| Q4-2024 | $10.49M ▲ | $20.47M ▲ | $-16.34M ▼ | -155.81% ▼ | $-1.29 ▼ | $-24.89M ▼ |
| Q3-2024 | $7.78M | $15.76M | $-10.67M | -137.21% | $-0.84 | $-10.93M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $23.73M ▼ | $196.51M ▼ | $35.3M ▼ | $161.29M ▲ |
| Q2-2025 | $27.71M ▼ | $199.11M ▼ | $48.21M ▲ | $150.98M ▼ |
| Q1-2025 | $58.53M ▼ | $204.01M ▼ | $42.9M ▲ | $160.88M ▼ |
| Q4-2024 | $62.81M ▲ | $213.57M ▼ | $42.23M ▼ | $170.39M ▼ |
| Q3-2024 | $42.83M | $235.77M | $55.67M | $178.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-12.41M ▼ | $0 | $0 | $0 | $0 | $0 |
| Q1-2025 | $-10.39M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q4-2024 | $-16.34M ▼ | $0 | $0 | $0 | $0 | $0 |
| Q3-2024 | $-10.67M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q2-2024 | $-10.72M | $0 | $0 | $0 | $0 | $0 |
CEO
Sheng Wu Yeung
Compensation Summary
(Year )
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
LMR PARTNERS LLP
Shares:1.3M
Value:$29.86K
ASPEX MANAGEMENT (HK) LTD
Shares:1.17M
Value:$26.72K
CALAMOS ADVISORS LLC
Shares:200K
Value:$4.58K
Summary
Showing Top 3 of 20